BioRestorative Therapies (BRTX) Receivables (2015 - 2025)

BioRestorative Therapies (BRTX) has reported Receivables for 11 consecutive years, with $15500.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Receivables fell 91.77% year-over-year to $15500.0; the trailing twelve-month figure through Dec 2025 stood at $15500.0 (down 91.77% YoY), and the FY2025 full-year result was $15500.0, down 91.77% from the prior year.
• Receivables advanced to $15500.0 in Q4 2025 per BRTX's latest filing, from $13400.0 in the prior quarter.
• Across five years, Receivables topped out at $188400.0 in Q4 2024 and bottomed at $5000.0 in Q4 2021.
• Historically, Receivables has averaged $36165.0 across 5 years, with a median of $17000.0 in 2021.
• The sharpest annual moves came in 2024 and 2025: Receivables jumped 876.17% in 2024, then sank 91.88% in 2025.
• Over 5 years, Receivables stood at $5000.0 in 2021, then soared by 220.0% to $16000.0 in 2022, then climbed by 20.62% to $19300.0 in 2023, then surged by 876.17% to $188400.0 in 2024, then slumped by 91.77% to $15500.0 in 2025.
• According to Business Quant data, Receivables over the past three periods registered $15500.0, $13400.0, and $15000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.